Gubra A/S (GUBRA.CO)
Gubra A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Horsholm, CR, DK. The stock last traded at $376.40, down 0.42% on the session, giving a market capitalisation of $6.18B. Its beta of 0.32 implies it has historically moved less than the broad market.
Gubra A/S is a biotechnology firm engaged in two core activities: offering contract research organization (CRO) services for pre-clinical development, and advancing its own internal early-stage drug and target discovery initiatives. Its CRO division provides specialized pre-clinical research and development support to companies in the pharmaceutical and biotechnology sectors. These services encompass a wide range of capabilities, including in vivo pharmacology, tissue analysis, various assay development, molecular pharmacology, bioanalytical testing, next-generation sequencing (NGS), and both two-dimensional and three-dimensional imaging techniques. Established in 2008, the company has its headquarters in Horsholm, Denmark.
Gubra A/S is most often compared with the following Healthcare names: